- Home
- NAAS vs VYNE Comparison
NAAS vs VYNE Comparison
Compare NAAS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | VYNE |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5M | 20.0M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NAAS | VYNE |
|---|---|---|
| Price | $2.41 | $0.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.8K | ★ 215.1K |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.29 |
| 52 Week High | $4.54 | $1.98 |
Technical Indicators
Market Signals| Indicator | NAAS | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 52.56 | 55.63 |
| Support Level | $2.22 | $0.56 |
| Resistance Level | $3.77 | $0.75 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 72.86 | 67.80 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.